Corona Remedies has guided for 15% organic revenue growth, with any contribution from future acquisitions expected to be incremental. The company also expects profit after tax (PAT) to grow at around 20% annually over the next three to five years, reflecting its confidence in sustaining long-term earnings growth.

Chief Financial Officer Bhavin Bhagat said" “We have a total of 76 brands, out of which 32 brands are engine brands. Engine brands are those brands that have the potential to cross ₹100 crore, and these 32 trials contribute 76% of the total revenue, which is growing by 19% since the last three years"”

Two brands — B-29 and Myoril — have already crossed into the ₹100-200 crore revenue range, according to Bhagat, with other engine brands working toward that milestone.

The stock was trading at ₹2,041.90 at 9:39 am on the NSE and has gained more than 41% over the past year.

The company believes recently acquired brands will further strengthen growth. Bhagat said the Wokadine portfolio, which generated around ₹20 crore in revenue internally, is expected to grow by around 25% annually over the next three years.

For the Bayer portfolio, which has been relaunched after the acquisition, Corona Remedies is targeting around ₹25 crore in revenue by the end of this year and aims to scale it to nearly ₹100 crore over the next three to four years.

CoronaRemedies'' operating margin came under pressure in the fourth quarter of fiscal year 2026 (the three months through March 2026), which Bhagat attributed to an expansion of thecompany'ss field sales force as part of a broader restructuring into separate business divisions."

"This margin expansion will cool down in FY27"" Bhagat said, referring to the fiscal year running from April 2026 to March 2027, adding that the benefits of the larger sales team — a dynamic known as operating leverage, where fixed costs are spread over rising revenue — should begin showing up in profitability from FY27 onward.

The company ended last fiscal year with margins of about 20-21%. Bhagat reiterated a medium-term target of 24% EBITDA margin — earnings before interest, tax, depreciation and amortisation, a common measure of core operating profitability — within four to five years.

CoronaRemedies'' current market capitalisation is ₹12,469.62 crore.